# A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

> **NCT04294667** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 321 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** DZP
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04294667
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-12
- **Primary completion:** 2024-05-22
- **Final completion:** 2024-06-04
- **Target enrollment:** 321 (ACTUAL)
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04294667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04294667, "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04294667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*